The United Kingdom (UK) has been severely affected by the Coronavirus Disease 2019 (COVID-19) pandemic. As the National Health Service (NHS) has urgently prioritised management of this outbreak, the UK clinical oncology community has had to adapt rapidly to maintain cancer services and training. These unprecedented times have altered countless aspects of cancer care, education and research, providing a legacy that will extend well beyond the pandemic which catalysed them. This editorial focuses on three key themes which distinguish the UK from many other countries.
|International Journal of Radiation: Oncology - Biology - Physics
|Accepted/In press - 21 Jun 2020